Trial · NCT00642902
Results by group28
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 28
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Mean Number of Time Constant 1 (T1) Gadolinium (Gd)-Enhancing Lesions Per Participant Per Scan | Placebo | 3.07 | 95% Confidence Interval 1.40 to 6.77 | lesions/participant/scan | |
| Mean Number of Time Constant 1 (T1) Gadolinium (Gd)-Enhancing Lesions Per Participant Per Scan | Atacicept 25 mg | 2.26 | 95% Confidence Interval 0.97 to 5.27 | lesions/participant/scan | |
| Mean Number of Time Constant 1 (T1) Gadolinium (Gd)-Enhancing Lesions Per Participant Per Scan | Atacicept 75 mg | 2.30 | 95% Confidence Interval 1.08 to 4.92 | lesions/participant/scan | |
| Mean Number of Time Constant 1 (T1) Gadolinium (Gd)-Enhancing Lesions Per Participant Per Scan | Atacicept 150 mg | 2.49 | 95% Confidence Interval 1.18 to 5.27 | lesions/participant/scan | |
| Number of New T1 Gd-enhancing Lesions Per Participant | Placebo | Week 12 (n=55, 45, 50, 55) | 2.55 | Standard Deviation 7.95 | lesions/participant |
| Number of New T1 Gd-enhancing Lesions Per Participant | Atacicept 25 mg | Week 12 (n=55, 45, 50, 55) | 2.71 | Standard Deviation 7.67 | lesions/participant |
| Number of New T1 Gd-enhancing Lesions Per Participant | Atacicept 75 mg | Week 12 (n=55, 45, 50, 55) | 3.20 | Standard Deviation 6.41 | lesions/participant |
| Number of New T1 Gd-enhancing Lesions Per Participant | Atacicept 150 mg | Week 12 (n=55, 45, 50, 55) | 2.96 | Standard Deviation 6.58 | lesions/participant |
| Number of New T1 Gd-enhancing Lesions Per Participant | Placebo | Week 24 (n=41, 34, 37, 41) | 0.83 | Standard Deviation 1.70 | lesions/participant |
| Number of New T1 Gd-enhancing Lesions Per Participant | Atacicept 25 mg | Week 24 (n=41, 34, 37, 41) | 1.50 | Standard Deviation 2.79 | lesions/participant |
| Number of New T1 Gd-enhancing Lesions Per Participant | Atacicept 75 mg | Week 24 (n=41, 34, 37, 41) | 1.54 | Standard Deviation 2.96 | lesions/participant |
| Number of New T1 Gd-enhancing Lesions Per Participant | Atacicept 150 mg | Week 24 (n=41, 34, 37, 41) | 1.54 | Standard Deviation 2.94 | lesions/participant |
| Number of New T1 Gd-enhancing Lesions Per Participant | Placebo | Week 36 (n=23, 22, 24, 26) | 0.43 | Standard Deviation 0.90 | lesions/participant |
| Number of New T1 Gd-enhancing Lesions Per Participant | Atacicept 25 mg | Week 36 (n=23, 22, 24, 26) | 1.68 | Standard Deviation 5.09 | lesions/participant |
| Number of New T1 Gd-enhancing Lesions Per Participant | Atacicept 75 mg | Week 36 (n=23, 22, 24, 26) | 1.38 | Standard Deviation 1.93 | lesions/participant |
| Number of New T1 Gd-enhancing Lesions Per Participant | Atacicept 150 mg | Week 36 (n=23, 22, 24, 26) | 0.54 | Standard Deviation 1.07 | lesions/participant |
| Percentage of Participants Free From Relapses | Placebo | 81.0 | percentage of participants | ||
| Percentage of Participants Free From Relapses | Atacicept 25 mg | 69.8 | percentage of participants | ||
| Percentage of Participants Free From Relapses | Atacicept 75 mg | 71.9 | percentage of participants | ||
| Percentage of Participants Free From Relapses | Atacicept 150 mg | 61.5 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00642902/results